We have set up this channel to give you convenient access to the latest research in the area of Cancer-associated thrombosis (CAT) by providing a customised feed of abstracts of clinical papers published on PubMed. The combination of search terms providing the feed below is 'cancer AND thrombosis'. This channel is sorted chronologically. To see more information about a given paper, click the ‘Preview Abstract’ button below, and this will reveal an expanded abstract.
Despite the well documented increased risk of thrombosis in patients with cancer and during chemotherapy, cerebral venous sinus thrombosis (CVT) remains a rare entity. We present a rare case of cerebrospinal fluid (CSF) rhinorrhoea secondary to a left transverse sinus thrombus which occurred 2 years previously during chemotherapy for breast cancer. The patient underwent a three-layer repair using Neuro-Patch, septal cartilage and middle turbinate pedicle flap and was started...
PURPOSE OF REVIEW: Patients with cancer are at high risk for thrombotic events, mainly deep vein thrombosis and pulmonary embolism. Low-molecular-weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the current treatment options for cancer-associated thrombosis (CAT). We assessed real world data (RWD) regarding treatment patterns of CAT from 1 September 2018 to 31 January 2020.
RECENT FINDINGS: RWD showed that LMWHs were the most common initial...
BACKGROUND: Adjuvant endocrine therapy is a gold standard in early-stage, hormone receptor positive breast cancer. In postmenopausal women, aromatase inhibitors (AIs) are associated with improved outcome compared to tamoxifen monotherapy. Differences in the toxicity profiles of these drugs are described; however, little is known about whether the risk of adverse events changes over time.
METHODS: Sequential reports of large, randomized, adjuvant endocrine therapy trials...
PMID: 32491261 [PubMed - as supplied by publisher]
BACKGROUND/AIM: Thrombosis internal jugular vein (IJV) with cervical adenopathy, as first manifestation of gastric cancer is rare. We aimed to compare resection of the cervical mass followed by gastrectomy with gastrectomy alone.
PATIENTS AND METHODS: Nine patients presenting thrombosis of the IJV for gastric carcinoma were divided into two groups. Patients in group A (n=3) underwent anticoagulation treatment, gastrectomy and adjuvant treatment. Patients in group B...
BACKGROUND: The ever-growing complexity of cancer-associated thrombosis (CAT), with new antineoplastic drugs and anticoagulants, distinctive characteristics, and decisions with low levels of evidence, justifies this registry.
METHOD: TESEO is a prospective registry promoted by the Spanish Society of Medical Oncology to which 34 centers contribute cases. It seeks to provide an epidemiological description of CAT in Spain.
RESULTS: Participants (N=939) with CAT...
BACKGROUND: Rivaroxaban, a novel oral anticoagulant drug, is widely used in clinical practice. There is no standardized laboratory monitoring for rivaroxaban, and its plasma concentration in Chinese patients with deep vein thrombosis is unclear. The rivaroxaban concentrations in human plasma and determine the steady-state concentration of rivaroxaban in patients with deep vein thrombosis are needed.
METHODS: An ultra-high-performance liquid chromatography with mass...
Pim kinases are upregulated in several forms of cancer, contributing to cell survival and tumour development, but their role in platelet function and thrombotic disease has not been explored. We report for the first time that Pim-1 is expressed in human and mouse platelets. Genetic deletion or pharmacological inhibition of Pim kinase results in reduced thrombus formation but is not associated with impaired haemostasis. Attenuation of thrombus formation was found to be due to...
This editorial summarizes and discusses the themes of eleven articles (five reviews and six original studies) published in the Special Issue "Molecular Research On Platelet Activity in Health and Disease". They give an international picture of the up-to-date understanding of i) platelet signalling under physiological and pathological conditions, ii) novel technologies for monitoring platelet functions and iii) clinical applications of platelet-based-therapy for management of...
AIM OF STUDY: Venous thromboembolic events (VTEs) are significant complications in patients with systemic malignancies. Thrombosis risk is poorly defined for patients with brain metastasis, and available risk calculation scores are not validated for these patients.
METHODS: We identified 811 patients with brain metastasis followed at our institution and reviewed electronic charts retrospectively for the occurrence of VTEs, along with candidate risk factors. Risk...
ICTHIC Lunchtime Symposium April 2018: Dr Marc Carrier
ICTHIC Lunchtime Symposium April 2018: Alexander Cohen
ICTHIC Lunchtime Symposium April 2018: Dr Florian Langer MD
ICTHIC Lunchtime Symposium April 2018: Dr Luis Jara-Palomares, MN, PhD
Structured Modules in CAT
Nov 21, 2016
Oct 28, 2016
Oct 27, 2016
Sep 29, 2016
Please fill out the following form with your login credentials:
This website is intended to provide non-promotional, educational information to an international healthcare professional audience only.
You have indicated that you are not a healthcare professional and therefore, do not have access to this site.Please click here to continue browsing
This website is owned by LEO Pharma.
Cookies by themselves cannot be used to discover the identity of the user, and they do not in any way damage your computer.
We use a Google Analytics cookie, further information can be seen here:: Google Analytics Cookie Usage
The browsers of most computers, smartphones and other web-enabled devices are typically set up to accept cookies. If you wish to amend your cookie preferences for this site or any other websites, you can do this through your browser settings. Your browser's 'help' function will tell you how to do this.
However, please remember that cookies are often used to enable and improve certain functions on our site. If you therefore choose to disable the cookies that we use, this may impact your experience while on www.cathrombosis.com, for example, you may not be able to visit certain areas of the site and you may not receive personalised information.
If you use different devices to view and access the site (e.g. your computer, smartphone, tablet etc.) you will need to ensure that each browser on each device is adjusted to suit your cookie preferences.
For more information on how to disable cookies, visit www.allaboutcookies.org